CarcinodermAlternative Names: Carcinoderm
Latest Information Update: 22 Feb 2007
At a glance
- Originator Bio-Life Labs
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Skin cancer
Most Recent Events
- 06 Sep 2004 Clinical trials in Skin cancer in USA (Topical)